Evidence map›Paper›PMID 22439695›Full record

ArticleMalaria journal2012

Antibodies to malaria vaccine candidates are associated with chloroquine or sulphadoxine/pyrimethamine treatment efficacy in children in an endemic area of Burkina Faso.

Amidou Diarra, Issa Nebie, Alfred Tiono, Issiaka Soulama, Alphonse Ouedraogo, Amadou Konate, Michael Theisen, Daniel Dodoo, Alfred Traore, Sodiomon B Sirima

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Host immunity toProceedings of the National Academy of Sciences of the United States of America · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Amidou DiarraCentre National de Recherche et de Formation sur le paludisme, o1 BP 2208 Ouagadougou 01, Burkina Faso. a.diarra.cnrfp@fasonet.bf
Issa Nebie
Alfred Tiono
Issiaka Soulama
Alphonse Ouedraogo
Amadou Konate
Michael Theisen
Daniel Dodoo
Alfred Traore
Sodiomon B Sirima
Centre National de Recherche et de Formation sur le Paludisme · BFGroupe de Recherche et d’Action sur le Foncier · BFNoguchi Memorial Institute for Medical Research · GHStatens Serum Institut · DKUniversité Joseph Ki-Zerbo · BF

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatient immune status is thought to affect the efficacy of anti-malarial chemotherapy. This is a subject of some importance, since evidence of immunity-related interactions may influence our use of chemotherapy in populations with drug resistance, as well as assessment of the value of suboptimal vaccines. The study aim was to investigate relationship between antibodies and anti-malarial drug treatment outcomes.

methodsSome 248 children aged 0.5 and 15 years were recruited prior to the high malaria transmission season. Venous blood (5 ml) was obtained from each child to measure antibody levels to selected malaria antigens, using ELISA. Blood smears were also performed to assess drug efficacy and malaria infection prevalence. Children were actively followed up to record clinical malaria cases.

resultsIgG levels to MSP3 were always higher in the successfully treated group than in the group with treatment failure. The same observation was made for GLURP but the reverse observation was noticed for MSP1-19. Cytophilic and non-cytophilic antibodies were significantly associated with protection against all three antigens, except for IgG4 to MSP1-19 and GLURP.

conclusionAcquired anti-malarial antibodies may play an important role in the efficacy of anti-malarial drugs in younger children more susceptible to the disease.

Indexed as

AdolescentAntibodies, ProtozoanAntimalarialsBiomarkersBurkina FasoChildChild, PreschoolChloroquineDrug CombinationsDrug Therapy, CombinationFemaleHumansImmunoglobulin GInfantMalaria, FalciparumMalaria VaccinesAntibodies, ProtozoanAntimalarialsBiomarkersChloroquineDrug Combinationsfanasil, pyrimethamine drug combinationImmunoglobulin GMalaria VaccinesProtozoan ProteinsPyrimethamineSulfadoxine

Identifiers

PMID22439695
PMCPMC3338389
OpenAlexW2114445005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.